Representatives

Maurya McLellan

mmclellan@castlebiosciences.com

(913) 269-7694

About

DecisionDx-Melanoma is a 31 gene expression profile test with extensive Prospective publications which provides comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma. By harnessing the genetic information within a patient’s tumor biology and incorporating traditional clinicopathologic features, DecisionDx-Melanoma helps to stratify patient risk and provide personalized results regarding a patient's risk of recurrence and/or metastasis and likelihood of sentinel lymph node positivity. DecisionDx-Melanoma can help to improve prognostic accuracy, better inform management decisions and positively impact outcomes – it is the only melanoma prognostic test associated with improved survival.

Representatives

Katie Jensen-Giessel

katie.jensen-giessel@galderma.com

(785) 969-1350

About



Galderma, founded in 1981, is a leading dermatology company operating in around 90 countries. It offers an innovative portfolio across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Committed to skin health, Galderma partners with healthcare professionals to provide superior outcomes for consumers and patients. The company strives to advance dermatology for every individual’s skin story. Visit Galderma’s website for more details.